BDBM498010 US11008314, Compound 135::US11008314, Compound 98

SMILES COc1cc(C)c(Sc2cnc(Nc3ccccn3)s2)cc1C(=O)N1CCN(CC1)C(=O)C=C

InChI Key InChIKey=OTCHPBVDCWVABU-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 498010   

TargetTyrosine-protein kinase BTK(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 10nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 10nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase TXK(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 10nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase TXK(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 10nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 10nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 10nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 55nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Corvus Pharmaceuticals

US Patent
LigandPNGBDBM498010(US11008314, Compound 135 | US11008314, Compound 98)
Affinity DataIC50: 550nMAssay Description:The potency of inhibition is measured by binding affinity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2021
Entry Details
US Patent